Table 1.
Demographic and Clinical Information for Longitudinal Sample
| Variable | Scan1-Scan2 (N = 80) | Scan2-Scan3 (N = 60) |
|---|---|---|
| Agea | 24.18 (3.99) | 24.97 (4.08) |
| Sex, M (%) | 56 (70%) | 44 (73.3%) |
| Right-handedness (N, %) | 67 (83.8) | 53 (88.3%) |
| SES | 3.12 (1.04) | 3.09 (0.97) |
| IQ | 99.96 (15.73) | 100.88 (16.12) |
| Years education | 11.93 (2.60) | 11.77 (2.60) |
| Interscan interval (mo) | 13.23 (1.29) | 12.64 (1.82) |
| % Non-remission | 59.91 (37.73) | 24.84 (32.47) |
| % Cannabis exposureb | 14.34 (26.52) [52] | 24.21 (38.90) [35] |
| CPZ equivalentsc | 3258.00 (2745.73) | 5090.50 (4776.30) |
| Adherence | 80.1 (24.3) | 75.27 (29.95) |
| DUP (wk) | 75.40 (145.94) | 77.84 (157.87) |
| Diagnosis (N, %) | ||
| Schizophrenia spectrum | 59 (73.8) | 42 (70.0) |
| Affective | 14 (17.5) | 12 (20.0) |
| Delusional disorder | 2 (2.5) | 2 (3.3) |
| Psychosis NOS | 5 (6.3) | 4 (6.7) |
| Other medication (N, %)d | ||
| Antidepressants | 11 (14.3) | 9 (16.7) |
| Benzodiazepines | 3 (3.9) | 3 (5.6) |
| Anticholinergics | 2 (2.6) | 1 (1.9) |
| Mood stabilizers | 8 (10.4) | 7 (13.0) |
Note: CPZ, chlorpromazine;DUP, duration of untreated psychosis;FUP1, follow-up year 1;FUP2, follow-up year 2;NOS, not otherwise specified;SES, socioeconomic status.General Demographics for whole sample are presented as a function of the 2 interscan intervals. Please see supplementary table 1 for clinical data presented separately for each timepoint.
aRefers to value at first scan in the contrast, ie, for Baseline-FUP1, age/SAPS at baseline is reported. For FUP1-FUP2, age/SAPS at FUP1 is reported.
bData missing for several patients. Number in square brackets represents adjusted N.
cCumulative CPZ equivalents at the second timepoint in the contrast are reported.
d3 and 6 patients were missing other medication data for the first and second interscan interval, respectively. Other medication data is reported based on the second timepoint in contrast, and proportions were calculated based on adjusted sample size.